Additionally, immunostaining analysis showed that ATG5 and ATG16L1 expression levels were significantly decreased in the HepG2/miR-142-3p xenografts compared with the HepG2/control tumour xenografts after sorafenib treatment (Fig. 7c). The gene discussed is ATG16L1; the disease is neoplasm.